{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
elacestrant
to a specific field?
There is one exact (name or code) match for elacestrant
Status:
US Approved Rx
(2023)
Source:
NDA217639
(2023)
Source URL:
First approved in 2023
Source:
NDA217639
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Elacestrant (ER-306323 or RAD 1901 [6R)-6-(2-(N-(4-(2-(ethylamino)ethyl)benzyl)-N-ethylamino)-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol dihydrochloride]) is a selective estrogen receptor (ER) degrader. Elacestrant induces the degradation of ER, inhibits ER-mediated signaling and growth of ER+ breast cancer cell lines in vitro and in vivo, and significantly inhibits tumor growth in breast cancer xenograft models. Elacestrant has the potential for use as a single agent or in combination with other therapies for the treatment of breast cancer. Elacestrant is being developed by Radius Health, for the treatment of estrogen receptor positive breast cancer.
Showing 1 - 3 of 3 results
Status:
US Approved Rx
(2023)
Source:
NDA217639
(2023)
Source URL:
First approved in 2023
Source:
NDA217639
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Elacestrant (ER-306323 or RAD 1901 [6R)-6-(2-(N-(4-(2-(ethylamino)ethyl)benzyl)-N-ethylamino)-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol dihydrochloride]) is a selective estrogen receptor (ER) degrader. Elacestrant induces the degradation of ER, inhibits ER-mediated signaling and growth of ER+ breast cancer cell lines in vitro and in vivo, and significantly inhibits tumor growth in breast cancer xenograft models. Elacestrant has the potential for use as a single agent or in combination with other therapies for the treatment of breast cancer. Elacestrant is being developed by Radius Health, for the treatment of estrogen receptor positive breast cancer.
Status:
US Approved Rx
(2023)
Source:
NDA217639
(2023)
Source URL:
First approved in 2023
Source:
NDA217639
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Elacestrant (ER-306323 or RAD 1901 [6R)-6-(2-(N-(4-(2-(ethylamino)ethyl)benzyl)-N-ethylamino)-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol dihydrochloride]) is a selective estrogen receptor (ER) degrader. Elacestrant induces the degradation of ER, inhibits ER-mediated signaling and growth of ER+ breast cancer cell lines in vitro and in vivo, and significantly inhibits tumor growth in breast cancer xenograft models. Elacestrant has the potential for use as a single agent or in combination with other therapies for the treatment of breast cancer. Elacestrant is being developed by Radius Health, for the treatment of estrogen receptor positive breast cancer.
